
-
Trump presses Syria leader on Israel after lifting sanctions
-
French PM to testify on child abuse scandal
-
Players stuck in middle with IPL, national teams on collision course
-
Peru PM quits ahead of no-confidence vote
-
Strikes kill 29 in Gaza as hostage release talks ongoing
-
Court raps Brussels for lack of transparency on von der Leyen vaccine texts
-
France summons cryptocurrency businesses after kidnappings
-
Pakistan returns Indian border guard captured after Kashmir attack
-
Baidu plans self-driving taxi tests in Europe this year
-
Trump meets new Syria leader after lifting sanctions
-
Equity markets swing as China-US trade euphoria fades
-
Burberry warns 1,700 jobs at risk after annual loss
-
Trump to meet new Syrian leader after offering sanctions relief
-
'Children are innocent': Myanmar families in grief after school air strike
-
Colombia joins Belt and Road initiative as China courts Latin America
-
Australian champion cyclist Dennis gets suspended sentence after wife's road death
-
Protection racket? Asian semiconductor giants fear looming tariffs
-
S. Korea Starbucks in a froth over presidential candidates names
-
NATO hatches deal on higher spending to keep Trump happy
-
Eurovision stage a dynamic 3D 'playground': producer
-
Cruise unleashes 'Mission: Impossible' juggernaut at Cannes
-
Suaalii in race to be fit for Lions Tests after fracturing jaw
-
Pacers oust top-seeded Cavs, Nuggets on brink
-
Sony girds for US tariffs after record annual net profit
-
China, US slash sweeping tariffs in trade war climbdown
-
Human Rights Watch warns of migrant worker deaths in 2034 World Cup host Saudi Arabia
-
Sony logs 18% annual net profit jump, forecast cautious
-
China, US to lift sweeping tariffs in trade war climbdown
-
Asian markets swing as China-US trade euphoria fades
-
Australian seaweed farm tackles burps to help climate
-
Judgment day in EU chief's Covid vaccine texts case
-
Trump set to meet Syrian leader ahead of Qatar visit
-
Misinformation clouds Sean Combs's sex trafficking trial
-
'Panic and paralysis': US firms fret despite China tariff reprieve
-
Menendez brothers resentenced, parole now possible
-
'Humiliated': Combs's ex Cassie gives searing testimony of abuse
-
Latin America mourns world's 'poorest president' Mujica, dead at 89
-
Masters champion McIlroy to headline Australian Open
-
Sean Combs's ex Cassie says he coerced her into 'disgusting' sex ordeals
-
McIlroy, Scheffler and Schauffele together for rainy PGA battle
-
Uruguay's Mujica, world's 'poorest president,' dies aged 89
-
Lift-off at Eurovision as first qualifiers revealed
-
Forest striker Awoniyi placed in induced coma after surgery: reports
-
'Kramer vs Kramer' director Robert Benton dies: representative
-
Tatum suffered ruptured right Achilles in playoff defeat: Celtics
-
US stocks mostly rise on better inflation data while dollar retreats
-
Winning farewell for Orlando Pirates' Spanish coach Riveiro
-
Lift-off at Eurovision as first semi-final takes flight
-
UN relief chief urges action 'to prevent genocide' in Gaza
-
Baseball pariahs Rose, Jackson eligible for Hall of Fame after league ruling

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1
or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Regeneron Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Regeneron stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
P.Keller--VB